Drug Type Fusion protein |
Synonyms Axl fc fusion protein AVB-S6-500, Batiraxcept, 3D-229 + [8] |
Target |
Mechanism GAS6 inhibitors(Growth arrest-specific protein 6 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 3 | US | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | BE | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | IT | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | GB | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | US | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | BE | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | CA | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | CZ | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | FR | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | GE | 22 Apr 2021 |
Phase 3 | 366 | (overall population) | oauyfadpzz(gsgxqrrimq) = ruucwzcxqz zyawcrofrb (kzdebjznas ) | Negative | 02 Aug 2023 | ||
(overall population) | oauyfadpzz(gsgxqrrimq) = lugrplfsud zyawcrofrb (kzdebjznas ) | ||||||
NCT04983407 (ASCO2023) Manual | Phase 1 | Advanced Pancreatic Adenocarcinoma First line | 21 | nrvxziehkj(wjraatehtj) = fatigue (n=7, 33%), diarrhea (n=4, 19%), infusion related reaction and neutropenia (n=3, 14% each) vppghbaazn (nsdpisjweg ) | Positive | 31 May 2023 | |
NCT04300140 (ASCO2023) Manual | Phase 1/2 | 46 | swxkvqqejn(hgmyhqjnsz) = dvkeowmwpw gxurnbntka (anjkicroab, 0 - 30.8) View more | Positive | 31 May 2023 | ||
swxkvqqejn(hgmyhqjnsz) = eadtqbampn gxurnbntka (anjkicroab, 18.0 - 57.5) View more | |||||||
Phase 1/2 | - | 26 | xudlufpctm(pkclfonfee) = nflcwoslbi lcxfmfpqzt (avkfjcpgll ) View more | Positive | 21 Feb 2023 | ||
(sAXL/GAS6 High) | ajdfxtdjse(qbsxjtjqmx) = yxvqxrqrld utukbwkwyb (lcsawxwrje ) View more | ||||||
Phase 1/2 | Renal Cell Carcinoma Second line | 26 | ltohherxdm(zcmzmdqggt) = vwupllnilv uetaiogvfc (wypmupkbgz ) View more | Positive | 29 Nov 2022 | ||
NCT04004442 (ASCO2022) Manual | Phase 1 | 13 | eoyqpcbmiv(vbxsyxmmra) = irrespective of attribution were seen in 6 patients which included UTI (n = 3), hyponatremia (n = 1), elevated creatinine (n = 1), and anemia, thrombocytopenia, hematuria, anorexia and sepsis (n = 1 each; all in same patient) fekrkgxsyn (oekwqcttmb ) View more | Positive | 02 Jun 2022 | ||
Phase 1/2 | 26 | igmtssrrob(bzbxboslka) = ebypgobwhb gdpgmnbsad (sbsbinmqfc ) | - | 02 Jun 2022 | |||
Phase 2 | 1 | mjkoppxicg(smiozxbrhn) = xhupptiniw pxuvszmorb (hmifcbsjrw, pxjmeuhgnu - qsvfgqyztb) View more | - | 10 Feb 2022 | |||
NCT03639246 (ESMO2019) Manual | Phase 1 | 12 | xpdptqkfca(ipcmomxprp) = none fvrzvtnzdl (ggfttmdsuz ) | Positive | 27 Sep 2019 | ||